A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab

The dramatic experience with SARS-CoV-2 has alerted the scientific community to be ready to face new epidemics/pandemics caused by new variants. Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein have represented good drugs to int...

Descripción completa

Detalles Bibliográficos
Autores principales: Passariello, Margherita, Ferrucci, Veronica, Sasso, Emanuele, Manna, Lorenzo, Lembo, Rosa Rapuano, Pascarella, Stefano, Fusco, Giovanna, Zambrano, Nicola, Zollo, Massimo, De Lorenzo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146290/
https://www.ncbi.nlm.nih.gov/pubmed/35628365
http://dx.doi.org/10.3390/ijms23105556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146290/
https://www.ncbi.nlm.nih.gov/pubmed/35628365
http://dx.doi.org/10.3390/ijms23105556

Ejemplares similares